Biogen Stock News

SAN FRANCISCO, Feb. 10, 2022 /PRNewswire/ -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: June 7, 2021 – Jan. 11,…

Biogen has a new proposal: the company will get Medicare the extra data it wants about the Alzheimer''s drug Aduhelm, but not through the slow, traditional trials Medicare is proposing.

Biogen has a new proposal: the company will get Medicare the extra data it wants on Aduhelm, but not through the slow trials it proposed.

Both offer yields more than twice what the S&P 500 provides.

Biogen may represent a very long-term buy.

Biogen may represent a very long-term buy.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Bio

Someone with a lot of money to spend has taken a bullish stance on Biogen (NASDAQ: BIIB ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with BIIB, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 10 uncommon options trades for Biogen. This isn''t normal. The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish. Out of all of the special options we uncovered, 2 are puts, for a total amount of $52,135, and 8 are calls, for a total amount of $568,809. What''s The Price Target? Taking into account the Volume and Open Interest on these Full story available on Benzinga.com

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.

NEW YORK, Feb. 9, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen, Inc. ("Biogen") (NASDAQ: BIIB) and certain of its officers, on behalf of shareholders who purchased or otherwise…

DUBLIN , Feb. 9, 2022 /PRNewswire/ -- The "Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)" report has been added to ResearchAndMarkets.com''s offering. The Global Alzheimer Drugs Market was valued at USD 6537.0 Million in the year 2021. The companies analysed in the report include AbbVie Inc., F. Hoffman-La Roche, Ltd., Novartis AG, Biogen, Pfizer Inc., Eli Lilli and Company, Takeda Pharmaceutical Company Limited, Novo Nordisk, Daiichi Sankyo Company Ltd., Eisai Co. Ltd, NervGen Pharma. Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer''s disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth.

SAN DIEGO--(BUSINESS WIRE)---- $BIIB #Aduhelm--Biogen Inc. (BIIB) Misled the Public and Investors Regarding the Viability of its Alzheimer''s Drug Aduhelm

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.

Biogen Inc (NASDAQ: BIIB ) and Xbrane Biopharma AB have entered into a license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody, a proposed biosimilar referencing UCB SA''s (OTC: UCBJY ) Cimzia (certolizumab pegol) Cimzia''s primary indication is for rheumatoid arthritis in Full story available on Benzinga.com